FDA Raises Substantial Concerns on LOTIS-5 Benefit-Risk; ADC Therapeutics Evaluates Regulatory Path
ADCT sits 53% above its 52-week low of $0.78 on light trading volume (0.3× avg).
Summary
ADC Therapeutics disclosed that the FDA raised substantial concerns about the LOTIS-5 trial's benefit-risk profile, jeopardizing full approval for ZYNLONTA. The company is evaluating its regulatory path forward while highlighting positive LOTIS-7 data and a cash runway into 2028.
Key Events · Product Development and Regulatory · ADCT
-
FDA Flags LOTIS-5 Benefit-Risk Concerns
At a pre-sBLA meeting, the FDA noted substantial concerns regarding the benefit-risk or verification of clinical benefit in LOTIS-5, citing an imbalance in Grade 5 events in the context of a marginal treatment benefit.
-
Regulatory Path for ZYNLONTA Uncertain
The company is assessing the best regulatory path forward for full approval and advancement into earlier lines of DLBCL. ZYNLONTA remains available under accelerated approval as a monotherapy in 3L+ DLBCL.
-
LOTIS-7 Enrollment Completed
The Phase 1b trial of ZYNLONTA plus glofitamab completed enrollment of 100 patients at the selected 150 µg/kg starting dose. Data submitted to ASH shows potential best-in-class bispecific combination data.
-
Cash Runway Extends into 2028
Cash and cash equivalents were $219.1 million as of June 30, 2026, down from $261.3 million at year-end 2025. The company expects cash runway at least into 2028.
Analysis · ADCT · Life Sciences
The FDA's pre-sBLA meeting feedback is a major setback for ZYNLONTA's full approval and expansion into earlier lines of DLBCL. The agency cited substantial concerns about the benefit-risk profile due to an imbalance in Grade 5 events, despite the trial meeting its primary PFS endpoint. This directly threatens the company's growth strategy and could limit ZYNLONTA's market opportunity. However, the company retains accelerated approval in 3L+ DLBCL and has $219.1 million in cash with runway into 2028, providing time to pursue alternative regulatory pathways or the LOTIS-7 combination.
At the time of this filing, ADCT was trading at $1.19 on NYSE in the Life Sciences sector, with a market capitalization of approximately $156.4M. The 52-week trading range was $0.78 to $4.98. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.